CDER guidance agenda
This article was originally published in The Rose Sheet
"Minimum Data Elements to be Included in a Serious Adverse Event Report for Monograph OTC Products" is one of 40 guidances the Center for Drug Evaluation and Research plans to develop during 2007. According to the March 19 release, the agenda items are "under development as of the date of this posting." Sunscreens, antiperspirants and treatments for dandruff and acne are among products regulated under FDA over-the-counter monographs. The "Dietary Supplement and Nonprescription Drug Consumer Protection Act of 2006" (S 3546), signed into law in late 2006 and effective in December, establishes mandatory reporting of serious adverse events associated with such products (1"The Rose Sheet" Jan. 29, 2007, p. 7). The list of guidances includes "Labeling of Over-the-Counter Skin Protectant Drug Products"...
You may also be interested in...
The compliance of companies newly subject to adverse event reporting and record-keeping requirements will likely be evaluated by FDA on a "performance-oriented basis," said Rick Kingston, PharmD, president and senior clinical toxicologist at SafetyCall International, an adverse event call center
AstraZeneca and Novavax have not filed EUAs for their vaccines, and they never might. The pathway remains viable in the short-term, but as BLAs are approved and supplies are no longer short, the window may close.
Emergency use authorization in 12-15 year-olds follows announcement of a June advisory committee meeting on pediatric data requirements, including the FDA’s criteria for younger children. Authorization for US adolescents has raised ethical questions about prioritizing this lower-risk group over hard-hit populations overseas.